Alexion Pays $610M to Buy Enobia for Hypophosphatasia ERT Candidate Genetic Engineering News ... Soliris and has leveraged its complement inhibition and antibody platforms to generate a clinical development-stage pipeline spanning the fields of hematologic, kidney and neurologic diseases, transplant rejection, cancer and autoimmune disorders. ... |
